Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients

Pulmonary Embolism Clinical Trial

Official title:

The Exploratory Study on Clinical Rational Use of Rivaroxaban Dosing in Elderly Chinese Population

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06194617
• Other study ID #: PUMCH-Rivaroxaban in Elderly
• Status: Recruiting
• Start date: April 1, 2021
• Est. completion date: September 30, 2026

Study information

• Verified date: December 2023
• Source: Peking Union Medical College Hospital
• Contact: juhong Shi, M.D
• Phone: +8513701178492
• Email: shijh[@]pumch.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur. While rivaroxaban typically doesn't require coagulation monitoring, in elderly patients, particularly those with multiple medications, finding appropriate lab indicators becomes crucial to gauge its anticoagulant effect. This aids in evaluating precise rivaroxaban dosing for the elderly, balancing bleeding risks and recurrence. Clinical pharmacological studies suggest that drug pharmacokinetics and pharmacodynamics in different populations can guide dosage optimization. Hence, this study aims to provide a basis for optimizing dosing regimens in high-risk elderly patients in China by exploring pharmacokinetic and pharmacodynamic indicators in clinical practice.

Description:

Comparison between the traditional anticoagulant warfarin and novel oral anticoagulants reveals the predictable pharmacokinetic and pharmacodynamic characteristics of the latter, with minimal influence from food and other medications, often eliminating the need for routine coagulation monitoring. As a representative of these novel oral anticoagulants, the Xa factor inhibitor rivaroxaban is widely used in the anticoagulant therapy of pulmonary embolism patients. Common adverse events associated with rivaroxaban include severe blood clots (such as pulmonary embolism) and bleeding events. This medication undergoes hepatic and renal dual-mode metabolism, with drug concentrations being influenced by both liver and kidney function. Studies indicate that in patients with impaired kidney function, using the recommended dose can lead to overdosing and increased risk of bleeding. Guidelines suggest that patients with mild renal impairment (creatinine clearance 50-80 mL/min) or moderate renal impairment (creatinine clearance 30-49 mL/min) do not require adjustment of rivaroxaban doses. For patients with severe renal impairment (creatinine clearance 15-29 mL/min), limited clinical data suggests significantly elevated blood drug concentrations with rivaroxaban, indicating its avoidance. For patients with impaired liver function: rivaroxaban is contraindicated in patients with coagulation abnormalities and clinically relevant bleeding risks, including those with Child-Pugh B and C stage cirrhosis. CYP3A4 and P-gp inhibitors elevate rivaroxaban blood concentrations, particularly evident in cases of renal impairment.

Elderly patients, characterized by declining renal function with age, multiple comorbidities, and polypharmacy, exhibit numerous uncertainties, often experiencing either over-anticoagulation or inadequate anticoagulation. Phase I clinical studies of rivaroxaban in healthy elderly individuals confirmed significant increases in pharmacodynamic parameters (Xa factor inhibition rate, PT) compared to younger individuals. The AUC (area under the curve) of Xa factor inhibition rate in the elderly was 41% higher than in younger individuals. This study attributed the results to declining renal function in the elderly. Population pharmacokinetic studies also confirm that after the age of 65, the complete clearance rate of rivaroxaban decreases annually by 1.05-1.5%.

Therefore, there's no unified recommendation in clinical practice regarding the necessity of adjusting corresponding dosing regimens in different patient types, especially when adverse events occur. While rivaroxaban typically does not require coagulation monitoring in most cases, in elderly patients, particularly those on multiple medications, there is a clinical need to identify suitable laboratory monitoring indicators to measure its anticoagulant efficacy, further assessing the optimal dosage for the elderly population to balance bleeding and recurrence risks. Clinical pharmacological studies indicate that the pharmacokinetic and pharmacodynamic characteristics of drugs in different populations can provide a basis for optimizing dosing regimens. Thus, this study aims to provide a basis for optimizing dosing regimens in the clinical practice of elderly high-risk patients in China through an exploration of the pharmacokinetic and pharmacodynamic indicators.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: September 30, 2026
• Est. primary completion date: September 30, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• (1) Adult patients with objectively diagnosed acute symptomatic pulmonary embolism (with or without concurrent deep vein thrombosis) by imaging, who have completed acute anticoagulation and entered the anticoagulation maintenance phase; (2) Life expectancy greater than 3 months; (3) Meeting the indications for Xa factor inhibitor use; (4) Willingness to participate in this study, sign the informed consent form, and adhere to regular follow-ups.

Exclusion Criteria:

• (1) Moderate or severe hepatic impairment (Child-Pugh Class B or C); (2) Severe renal impairment (CrCl < 15ml/min); (3) Pregnant or breastfeeding women; (4) Spontaneous bleeding tendencies, such as coagulation disorders or low platelet count (PLT < 20×10^9/L); (5) Contraindications to other Xa factor inhibitors' usage; (6) Patients diagnosed with hereditary thrombophilia and antiphospholipid syndrome.

Related Conditions & MeSH terms

• Anticoagulant-induced Bleeding
• Embolism
• Pulmonary Embolism
• Thromboembolism
• Venous Thromboembolism

Intervention

Drug:
• Direct oral anticoagulant
Patients take DOACs according to their condition, with the dosage determined by the clinical physician.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Symptomatic recurrence of VTE.	Recurrent VTE.	through study completion, an average of 1 year
Primary	Fatal or non-fatal PTE.	Recurrent VTE.	through study completion, an average of 1 year
Primary	Major bleeding (MB) and clinically relevant non-major bleeding (CRNMB) events as defined by the International Society on Thrombosis and Haemostasis (ISTH).	Bleeding Events	through study completion, an average of 1 year